Daxor Corporation announced new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world?s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, MassachusettsMarch 4-6, 2024. The study, titled, ?Blood Volume Profiles and Correlations with Pressures in Heart Failure with Impaired Renal Function,?

aimed to answer if the degree of renal impairment in heart failure patients impacts volume status, the pressure-volume relationship, and the prevalence and types of anemia. Veraprapas Kittipibul M.D., lead investigator of the study concluded that: Heterogeneity in volume exists across renal function which can only be accurately measured with BVA. Patients with large volume expansion had worsening renal function, showing the urgent need for care.

Pressure-volume correlation is consistently weak across renal function, showing that BVA is the right tool. Anemia, especially dilutional anemia, is more prevalent in worse renal function, also detectable by BVA.